No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis

Hepatology

Volumn 41, Issue 3, 2005, Pages 595-602

  Dilger, Karin ^a   Denk, Annette ^b   Heeg, Malte H J ^b   Beuers, Ulrich ^b  

^a Dr Falk Pharma GmbH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYPREDNISOLONE; 6BETA HYDROXYBUDESONIDE; 6BETA HYDROXYHYDROCORTISONE; BIOLOGICAL MARKER; BUDESONIDE; CYTOCHROME P450 3A; DRUG METABOLITE; HYDROCORTISONE; RIFAMPICIN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; BIOTRANSFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FEMALE; HUMAN; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; URINARY EXCRETION;

ADULT; AGED; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BUDESONIDE; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; HYDROCORTISONE; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; URSODEOXYCHOLIC ACID;

EID: 14244269427     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20568     Document Type: Article

References (49)

1. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. HEPATOLOGY 2002;36:525-531.
2. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid: mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol 2001;35:134-146.
3. Trauner M, Graziadei IW. Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther 1999;13:979-996.
4. Leuschner U, Fischer H, Kurtz W, Leuschner M. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989;97:1268-1274.
5. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991;324:1548-1554.
6. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. HEPATOLOGY 1994;19:1149-1156.
7. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-1290.
8. Combes B, Carithers RL Jr., Maddrey WC, Lin D, McDonald MF, Wheeler DE, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. HEPATOLOGY 1995;22:759-766.
9. Pares A, Caballeria L, Rodes J, Bruguera M, Rodrigo L, Garcia-Plaza A, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000;32:561-566.
10. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. HEPATOLOGY 2000;32:1196-1199.
11. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-890.
12. Poupon RE, Bonnand AM, Chretien Y, Poupon R. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. HEPATOLOGY 1999;29:1668-1671.
13. Goulis J, Leandro G, Burroughs A. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999;354:1053-1060.
14. Lindor KD, Poupon R, Heathcote EJ, Therneau T. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet 2000;355:657-658.
15. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2002;1:CD000551.
16. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug mecabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17.
17. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430.
18. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
19. Xie HG, Wood AJJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004;5:243-272.
20. Doherry MM, Charman WN. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 2002;41:235-253.
21. Paolini M, Pozzetti L, Piazza F, Cantelli-Forti G, Roda A. Bile acid structure and selective modulation of murine hepatic cytochrome P450-linked enzymes. HEPATOLOGY 1999;30:730-739.
22. Paolini M, Pozzetti L, Montagnani M, Potenza G, Sabatini L, Antelli A, et al. Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up-regulation of CYP [correction of CXP] and preservation of BSEP activities. HEPATOLOGY 2002;36:305-314.
23. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 2001;276:39411-39418.
24. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broome U, Einarsson C, et al. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome P450 3A4. J Biol Chem 2001;276:38685-38689.
25. Jonsson G, Astrom A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos 1995;23:137-142.
26. Leuschner M, Maier KP, Schlichting J, Strahl S, Herrmann G, Dahm HH, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999;117:918-925.
27. Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. HEPATOLOGY 2003;38:196-202.
28. Galteau MM, Shamsa F. Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and animals. Eur J Clin Pharmacol 2003;59:713-733.
29. Flockhart DA. Drug interactions - cytochrome P450 system. Available at: http://medicine.iupui.edu/flockhart.
30. Lykkesfeldt J, Loft S, Poulsen HE. Simultaneous determination of urinary free cortisol and 6beta-hydroxycortisol by high-performance liquid chromatography to measure human CYP3A activity. J Chromatogr B Biomed Appl 1994;660:23-29.
31. Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. HEPATOLOGY 1992;16:707-714.
32. Prince MI, James OF, Holland NP, Jones DE. Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use. J Hepatol 2000;32:368-373.
33. George J, Murray M, Byth K, Farrell GC. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. HEPATOLOGY 1995;21:120-128.
34. Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M, et al. Sex is a major determinant of CYP3A4 expression in human liver. HEPATOLOGY 2003;38:978-988.
35. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, et al. The effect of age, sex, and rifampicin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 2003;74:275-287.
36. Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992;102:2077-2080.
37. Mela M, Mancuso A, Burroughs AK. Review article: pruritus in cholestatic and other liver diseases. Aliment Pharmacol Ther 2003;17:857-870.
38. Glasova H, Beuers U. Extrahepatic manifestations of cholestasis. J Gastroenterol Hepatol 2002;17:938-948.
39. Goodwin B, Redinbo MR, Kliewer SA. Regulation of CYP3A gene transcription by the pregnane X receptor. Annu Rev Pharmacol Toxicol 2002;42:1-23.
40. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampicin. J Biol Chem 2001;276:14581-14587.
41. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 2002;123:1649-1658.
42. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin. Clinical relevance. Clin Pharmacokinet 2003;42:819-850.
43. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampicin. HEPATOLOGY 1996;24:796-801.
44. Von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto K. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004;75:172-183.
45. Dilger K, Schwab M, Fromm MF. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis 2004;10:578-583.
46. Kojima H, Nies AT, Konig J, Hagmann W, Spring H, Uemura M, et al. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J Hepatol 2003;39:693-702.
47. Lee KH, Shin JG, Chong WS, Kim S, Lee JS, Jang JI, et al. Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampicin. Eur J Clin Pharmacol 1993;45:287-289.
48. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998;54:53-58.
49. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampicin. J Clin Invest 1999;104:147-153.